Koyfin Home > Directory > Health Care > LA Jolla Pharma > Gross Margin

LA Jolla Pharma Gross Margin Chart (LJPC)

LA Jolla Pharma annual/quarterly Gross Margin from 2015 to 2020. Gross margin is a company's total sales revenue minus its cost of goods sold (COGS), divided by total sales revenue, expressed as a percentage. The higher the percentage, the more the company retains on each dollar of sales, to service its other costs and debt obligations.
  • LA Jolla Pharma Gross Margin for the quarter ending June 06, 2020 was $86m a 426.36% increase of 367m year over year
  • LA Jolla Pharma Gross Margin for the last 12 months ending June 06, 2020 was $89m a -381.26% decrease of -340m year over year
  • LA Jolla Pharma Annual Gross Margin for 2019 was $90m a 6.65% increase of 6m from 2018
  • LA Jolla Pharma Annual Gross Margin for 2018 was $84m a 12,066.91% increase of 10,095m from 2017
  • LA Jolla Pharma Annual Gross Margin for 2016 was $-10,012m a 73.51% decrease of -7,359m from 2015
Other Margins & Efficiency Metrics:
  • LA Jolla Pharma EBITDA Margin for the quarter ending March 03, 2009 was $-39m a -250.00% increase of 96m year over year
  • LA Jolla Pharma Return on Capital % for the quarter ending September 09, 2018 was -55.05 a -69.64% increase of 38.33 year over year
  • LA Jolla Pharma Return on Equity % for the quarter ending September 09, 2018 was -212.92 a 30.37% decrease of -64.67 year over year
View Chart On Koyfin

Quarterly LJPC Gross Margin Data

06/2020$86m
03/2020$91m
12/2019$978m
09/2019$-281m
06/2019$90m
03/2019$89m
12/2018$2,216m
09/2018$-785m
06/2018$-1,846m
03/2018$-3,421m

Annual LJPC Gross Margin Data

2019$90m
2018$84m
2016$-10,012m
2015$-2,652m